Vertex Pharmaceuticals (NASDAQ:VRTX) Given New $600.00 Price Target at Oppenheimer

Vertex Pharmaceuticals (NASDAQ:VRTX) had its price objective lifted by Oppenheimer from $540.00 to $600.00 in a research note released on Tuesday, Marketbeat reports. The firm currently has an outperform rating on the pharmaceutical company’s stock.

Other analysts also recently issued reports about the company. Wells Fargo & Company upped their target price on Vertex Pharmaceuticals from $460.00 to $515.00 and gave the company an “overweight” rating in a research report on Wednesday, December 10th. Weiss Ratings upgraded Vertex Pharmaceuticals from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Wednesday, February 4th. UBS Group upped their price target on shares of Vertex Pharmaceuticals from $535.00 to $545.00 and gave the company a “buy” rating in a research report on Monday, January 26th. Wolfe Research upgraded shares of Vertex Pharmaceuticals from a “peer perform” rating to an “outperform” rating and set a $548.00 target price on the stock in a research report on Tuesday, January 6th. Finally, Scotiabank raised their price target on shares of Vertex Pharmaceuticals from $495.00 to $558.00 and gave the company an “outperform” rating in a research report on Friday, February 13th. Twenty-three investment analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $551.77.

Vertex Pharmaceuticals Stock Up 8.3%

NASDAQ:VRTX opened at $499.17 on Tuesday. The firm has a market capitalization of $126.80 billion, a P/E ratio of 32.56 and a beta of 0.31. Vertex Pharmaceuticals has a 12-month low of $362.50 and a 12-month high of $519.68. The stock’s fifty day simple moving average is $468.41 and its 200-day simple moving average is $436.53.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its earnings results on Thursday, February 12th. The pharmaceutical company reported $5.03 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $5.05 by ($0.02). The business had revenue of $3.19 billion for the quarter, compared to the consensus estimate of $3.18 billion. Vertex Pharmaceuticals had a return on equity of 24.30% and a net margin of 32.94%.Vertex Pharmaceuticals’s revenue for the quarter was up 9.5% compared to the same quarter last year. During the same period in the previous year, the company posted $3.98 earnings per share. As a group, equities research analysts expect that Vertex Pharmaceuticals will post 15.63 earnings per share for the current year.

Insider Buying and Selling

In related news, EVP Duncan Mckechnie sold 4,910 shares of Vertex Pharmaceuticals stock in a transaction that occurred on Wednesday, February 25th. The stock was sold at an average price of $487.65, for a total transaction of $2,394,361.50. Following the sale, the executive vice president directly owned 17,559 shares in the company, valued at $8,562,646.35. The trade was a 21.85% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Mark E. Bunnage sold 2,021 shares of the business’s stock in a transaction dated Wednesday, February 11th. The stock was sold at an average price of $460.43, for a total transaction of $930,529.03. Following the sale, the executive vice president directly owned 12,914 shares in the company, valued at $5,945,993.02. The trade was a 13.53% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 91,156 shares of company stock worth $42,845,497 over the last 90 days. Insiders own 0.20% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the business. Vanguard Group Inc. lifted its holdings in shares of Vertex Pharmaceuticals by 1.0% during the 3rd quarter. Vanguard Group Inc. now owns 24,216,865 shares of the pharmaceutical company’s stock valued at $9,484,293,000 after buying an additional 243,088 shares during the period. Capital Research Global Investors lifted its position in shares of Vertex Pharmaceuticals by 4.6% in the fourth quarter. Capital Research Global Investors now owns 17,316,344 shares of the pharmaceutical company’s stock worth $7,850,544,000 after buying an additional 763,063 shares in the last quarter. State Street Corp lifted its position in Vertex Pharmaceuticals by 0.7% during the fourth quarter. State Street Corp now owns 11,689,539 shares of the pharmaceutical company’s stock valued at $5,299,569,000 after purchasing an additional 83,539 shares during the last quarter. Geode Capital Management LLC raised its position in Vertex Pharmaceuticals by 2.9% during the second quarter. Geode Capital Management LLC now owns 5,928,747 shares of the pharmaceutical company’s stock valued at $2,627,135,000 after purchasing an additional 166,987 shares during the period. Finally, Capital International Investors raised its holdings in Vertex Pharmaceuticals by 0.9% during the 4th quarter. Capital International Investors now owns 4,733,596 shares of the pharmaceutical company’s stock valued at $2,146,041,000 after buying an additional 44,537 shares during the period. 90.96% of the stock is owned by institutional investors.

Trending Headlines about Vertex Pharmaceuticals

Here are the key news stories impacting Vertex Pharmaceuticals this week:

• Positive Sentiment: Vertex reported positive Week‑36 interim results from the Phase 3 RAINIER trial for povetacicept — the study met its primary and all secondary endpoints, supporting the drug’s potential as a best‑in‑class treatment for IgA nephropathy. Vertex Announces Positive Week 36 Interim Analysis Results
• Positive Sentiment: News outlets note the trial win as a major validation — coverage emphasizes the result as a “key test” passed and calls the data “remarkable,” boosting confidence in Vertex’s kidney‑disease strategy. Vertex passes key test In quest to treat kidney diseases
• Positive Sentiment: Interim efficacy metrics cited in coverage (e.g., ~52% reduction in proteinuria) raise hopes for meaningful clinical benefit and potential for an accelerated FDA filing pathway, increasing the drug’s peak‑sales and valuation assumptions. VRTX Stock Gains on Upbeat Interim Data From Kidney Disease Drug Study
• Positive Sentiment: Multiple brokerages responded quickly with higher price targets and fresh buy/outperform ratings (examples: Morgan Stanley, BofA, Oppenheimer, HC Wainwright, Citi, Jefferies, BMO and others), reflecting analysts modeling substantial upside from povetacicept. Benzinga — analyst price target coverage
• Neutral Sentiment: Vertex presented at the Leerink Global Healthcare Conference (transcript available), which may provide additional detail on timing, filing plans and commercial strategy but is less market‑moving than the trial headlines. Vertex Presents at Leerink Global Healthcare Conference 2026 Transcript
• Neutral Sentiment: Market commentary and aggregator pieces (Barron’s, Yahoo, Investopedia, TipRanks) are amplifying the newsflow — helpful for liquidity and momentum but reflecting the same core trial announcement rather than new independent data. Investopedia — trial results coverage

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Inc is a Boston-based biotechnology company focused on the discovery, development and commercialization of therapies for serious diseases. Founded in 1989, Vertex built its reputation on research-driven drug development and is best known for its work in cystic fibrosis (CF), where its portfolio of small-molecule CFTR modulators transformed standards of care for many people with the disease. The company operates research and development, manufacturing and commercial organizations and serves patients and healthcare systems in multiple international markets.

Vertex’s marketed products center on CFTR modulators that target the underlying cause of cystic fibrosis rather than just treating symptoms.